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JM216 (bis acetato ammine dichlorocyclohexylamine platinum
IV) is an orally administered platinum (Pt) compound which has
been evaluated in phase II clinical trials against small-cell lung
cancer, non-small-cell lung cancer, prostate and ovarian cancer
and is currently undergoing phase III clinical evaluation
(McKeage et al, 1995). It was selected as the lead compound of a
series of ammine/amine Pt (IV) dicarboxylates, designed to show
improved lipophilicity and gastrointestinal (GI) stability in an
effort to overcome the limited GI absorption observed with
cisplatin and carboplatin (Giandomenico et al, 1991; Harrap et al,
1991).
In preclinical studies, JM216 exhibited activity comparable
to that of cisplatin against a panel of in vitro human ovarian
carcinoma cell (HOC) lines (Kelland et al, 1993), lung cancer
(Twentyman et al, 1992) and human cervical squamous cells
(Mellish et al, 1993), and exhibited non-cross-resistance to
cisplatin in a panel of six pairs of acquired resistant and parent
human tumour lines, notably where resistance was mediated
through reduced Pt uptake (Kelland et al, 1992a, 1993).
JM216 undergoes extensive biotransformation in vitro and
in vivo and several metabolites, each of which show growth
inhibitory activity, have been identified (Poon et al, 1995;
Raynaud et al, 1996a, 1996b). The metabolic profile of JM216 in
vitro was found to be dependent upon glutathione levels (Raynaud
et al, 1996b). For example, in SKOV-3 cells with twice the
glutathione content level of CH1, glutathione adducts accounted
for 89% of total Pt, compared with 24% in the CH1.
Our previous studies with cisplatin in the CH1 cell line, its
acquired resistant variant, CH1cisR and the intrinsically resistant
SKOV-3 cell line, showed that there was no difference in platinum
accumulation, Pt binding to DNA or global removal of Pt adducts
from DNA. However, resistance could be related to reduced
formation of interstrand cross-links (ISCs) (O’Neill et al, 1995). In
recent years the importance of gene-specific repair in platinum
resistance has been well documented (Zhen et al, 1992; Johnson
et al, 1994; Koberle et al, 1996, 1997; Petersen et al, 1996). For
example, it was demonstrated that Pt/DNA lesions induced in the
DHFR gene were repaired in the Pt-resistant L1210 cells
compared with the parental line when no difference was observed
in the overall removal of total Pt (Petersen et al, 1996).
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Summary JM216, an oral platinum drug entering into phase III clinical trial, exhibited comparable cytotoxicity to cisplatin in three human
ovarian carcinoma cell lines: the sensitive (CH1), acquired resistant (CH1cisR) and intrinsically resistant (SKOV-3). Platinum accumulation
and binding to DNA were similar in each of the three cell lines at equimolar doses, indicating that the resistant cell lines could tolerate higher
intracellular platinum levels and platinum bound to DNA at IC50 concentrations of drug. Comparison with cisplatin demonstrated that
intracellular platinum levels were marginally higher with JM216, but that platinum binding to DNA was similar for the two drugs in each of the
cell lines. Each of the cell lines exhibited an ability to repair JM216 induced platinum/DNA lesions in the N-ras gene (gene-specific repair) at
equitoxic concentrations of drug. However, this occurred to a greater extent in the two resistant cell lines such that by 24 h the CH1cisR and
SKOV-3 had removed 72% and 67% respectively compared with approximately 32% for the CH1. Reduced gene-specific repair capacity in
CH1 cells was also seen following incubation with 25 mM (or 5 mM – 2 ´ IC50) cisplatin, whereas the CH1cisR and SKOV-3 cell lines were repair
proficient. JM216 induced apoptosis in the three cell lines following a 2h incubation with 2 ´ the IC50 of drug. Fluorescent microscopy of cells
stained with propidium iodide showed that the detached cell population displayed typical apoptotic nuclei. Furthermore, field inversion gel
electrophoresis demonstrated the presence of DNA fragments approximately 23–50 kb in size, indicative of apoptosis, in the detached cells.
JM216 induced an S phase slow down in each of the three cell lines accompanied by a G2 block in the CH1 pair. Incubation with this
concentration of JM216 also resulted in the induction of p53 in the CH1 and CH1cisR. These studies suggest that the relative sensitivity of the
CH1 cell line to cisplatin and JM216 is at least partly attributable to a deficiency in gene-specific repair. The oral platinum drug, JM216, exerts
its cytotoxic effects through the induction of apoptosis following a slow-down in S phase in both the sensitive and resistant lines. © 1999
Cancer Research Campaign
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Furthermore, the sensitivity of testis tumour cell lines to cisplatin
corresponded with a lack of gene-specific repair of lesions induced
in the N-ras gene compared with repair competent bladder cell
lines, more resistant to cisplatin (Koberle et al, 1996, 1997).
Cisplatin and two novel Pt compounds, JM149 and JM335,
were shown to induce apoptosis in these cell lines (Ormerod et al,
1996; O’Neill et al, 1996). The protein p53 is known to induce
either a G1 arrest or trigger apoptosis following exposure to geno-
toxic agents including ionizing radiation and cisplatin (Kastan
et al, 1991; Lowe et al, 1993, 1994; Hainaut, 1995). These cell
lines have been shown to differ in their p53 status, the CH1 and
CH1cisR being wild-type for p53 and the SKOV-3, null
(Yaginuma and Westphal, 1992; Pestell et al, 1998).
The aim of this study was to determine the cellular pharma-
cology of JM216 in the CH1, CH1cisR and SKOV-3 cell lines.
The variables studied were DNA binding and removal at the level
of a portion of the N-ras gene, apoptosis, cell cycle effects and the
effects on the induction of p53.
MATERIALS AND METHODS
Drugs and chemicals
Cisplatin and JM216 were synthesized and obtained from The
Johnson Matthey Technology Centre (Reading, Berkshire, UK).
Both drugs were dissolved in sterile 0.9% sodium chloride (NaCl)
and sterile filtered prior to use. Platinum atomic absorption
standard was purchased from Aldrich Chemical Company
(Gillingham, Dorset, UK). Phenol (Ultrapure), Dulbecco’s modi-
fied Eagles’ medium (DMEM), trypsin (0.25%) EDTA and cell
culture supplements, were purchased from Gibco-BRL (Uxbridge,
Middlesex, UK). Novex precast polyacrylamide electrophoresis
(PAGE) gels, running and transfer buffers, and nitrocellulose
membranes were purchased from R&D systems (Abingdon,
Oxford, UK). Monoclonal antibodies and Pierce BCA protein
assay reagent kit, were bought from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and Pierce (Rockford, IL, USA) respec-
tively. Forward and reverse primers for QPCR, Buffer IV, NaCl
and Taq polymerase were purchased from Oswell DNA Service
(Southampton, UK). Radiochemicals and Rainbow standard
markers, enhanced chemiluminescence reagents (ECL) and Hyper
film-ECL were obtained from Amersham International plc
(Aylesbury, Bucks, UK) and all other reagent chemicals and
enzymes were purchased from Sigma Chemical Co. Ltd (Poole,
Dorset, UK) unless otherwise stated.
Cell culture
Three human ovarian carcinoma cell lines; the CH1 parent,
CH1cisR (with acquired resistance to cisplatin) and the intrinsi-
cally resistant SKOV-3, were used in these experiments (Fogh
et al, 1977; Hills et al, 1989; Kelland et al, 1992b). Cells were
cultured as monolayers in DMEM supplemented with 10% heat-
inactivated fetal calf serum (FCS), MEM non-essential amino
acids, 2 mM glutamine and 0.4 mg ml–1 hydrocortisone. Under
these conditions CH1 cell lines exhibited a doubling time of
around 17 h while that of the SKOV-3 cell line was approximately
22 h. Cells in culture were periodically tested and found to be
free of Mycoplasma using the MycoTect kit (Life Science
Technologies).
Growth inhibition
The effects of JM216 on cell proliferation were measured using
the sulphorhodamine B (SRB) assay (Kelland et al, 1992a).
Briefly, cells were incubated with a range of drug concentrations
(in quadruplicate) for 2 h followed by 96 h in drug-free medium.
At the end of the 96h period, medium was removed, cells were
fixed for 30 min at 4°C with 10% w/v trichloroacetic acid (TCA),
and then washed four times with water. The plates were then air-
dried and a 0.4% SRB solution in 1% acetic acid added for 10–15
min. The plates were then washed four times with 1% acetic acid
and air dried overnight. The SRB was solubilized with 100 ml of
10 mM Tris and the resultant colour intensity quantitated at 540 nm
using a Titertek Multiscan MCC/340 (Flow Laboratories). The
IC50 was determined using Titersoft computer software to deter-
mine the concentration of drug, which reduced absorbance by
50%. In these experiments the 2 h IC50 obtained for the CH1 (3.8 mM)
and SKOV-3 (40.5 mM) were similar to those published in other
studies (Mellish et al, 1994; Raynaud et al, 1996), the SKOV-3
being approximately 10.6-fold more resistant to JM216.
Platinum accumulation
Intracellular (Pt) levels were measured following a 2h exposure to
10 mM,2 5mM,5 0mM and 100 mM concentrations of drug. Cells at
approximately 2 ´ 106 were washed twice with 10ml volumes of
ice-cold phosphate-buffered saline (PBS-4°C) and the monolayer
scraped into 2 ml ice-cold PBS. The cell suspensions were then
sonicated on ice (2 ´ 30 s pulses at an amplitude of 20 mm) using a
Soniprep 150 (Fisons, Loughborough, UK). Pt content was
determined by flameless atomic absorption spectroscopy (FAAS)
using a Perkin-Elmer 1100B/HGA 700 (Beaconsfield, Bucks,
UK). Aliquots of cell sonicate were automatically injected into the
graphite furnace and the ng Pt ml–1 of sample measured by
comparison with Pt standards 40–200 ng ml–1, dissolved in 0.2%
nitric acid. Under these conditions the limit of detection was
between 5 and 10 ng Pt ml–1. Protein content was measured by the
method of Lowry et al (1951), where 100 ml of cell sonicate was
hydrolysed overnight in a final volume of 1 ml 1 N sodium
hydroxide before assay and results were expressed as nmol Pt mg–1
protein.
Determination of Pt bound to DNA
Cells (5 ´ 107) were incubated with a range of drug concentrations
(10–100 mM) for 2 h and removed from the monolayer by incuba-
tion with trypsin–EDTA (0.25%) for 5 min and DNA extracted.
Briefly, the trypsin was neutralized with an equal volume of
supplemented DMEM, cells were harvested by centrifugation,
washed twice with ice-cold PBS, suspended in 2.5 ml of lysing
solution (10 mM Tris, 10 mM EDTA, 150 mM sodium chloride
(NaCl), sodium dodecyl sulphate (SDS) 0.4%, 1 mg ml–1
proteinase K) and placed at 65°C for 15 min. Residual protein was
removed with addition of an equal volume of phenol reagent
(500 g phenol, 75 ml M-cresol, 55 ml water, 0.5 g hydroxyquino-
line) (Kirby and Cook, 1967). Following centrifugation at 2000 g
for 20 min the aqueous phase was removed, sodium acetate added
(0.3 M final concentration) and nucleic acids precipitated by the
addition of 2.5 volumes of 100% ethanol. The precipitates were
washed twice in 80% ethanol by centrifugation, the resultant
pellets were dissolved in 5 ml of 10 mM Tris/0.1 mM EDTA pH 7.71296 CF O’Neill et al
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and incubated with heat inactivated RNAase (0.1mg ml–1 final
concentration) at 37°C for 1h. The solutions were re-extracted
with phenol reagent and DNA precipitated as above. Dried DNA
pellets were dissolved overnight at 37°C in 0.2% nitric acid and
platinum content measured by FAAS, DNA content was measured
using the Burton assay (1956) and results were expressed as
pmoles of Pt per mg of DNA.
Measurement of Pt/DNA lesions using quantitative PCR
Formation and removal of platinum induced lesions was measured
in the N-rasgene following the method outlined by Grimaldi et al
(1994) and Koberle et al (1996). Cells in mid-log phase were incu-
bated for 5h with drug in order to optimize detection of lesions (B
Koberle, unpublished observations) and collected as above imme-
diately after removal of drug or following a 24h incubation in
drug-free medium. Approximately 106 cells were lysed in a 2ml
Eppendorf in 340ml of lysis solution (400mMTris pH 8, 60mM
EDTA, 150mMNaCl, 1% w/v SDS) plus 100ml 5Msodium
perchlorate, by mixing at room temperature for 20min and then at
65°C for a further 20min. Then, 580ml of chloroform was added
to the lysate, the solution mixed on a rotary mixer for 20min at
room temperature followed by centrifugation in a microfuge at top
speed for 10min. Following centrifugation, the upper layer was
aliquoted into a new Eppendorf and nuclear material precipitated
in 2 volumes of absolute ethanol. The precipitate was washed
twice in 70% ethanol, dried in an incubator overnight at 37°C and
dissolved in 400ml water. Polymerase chain reaction (PCR) was
performed using 25ml of sample in a final volume of 100ml
containing: 2 units (0.2ml) of Taqpolymerase (red hot), 4.8ml of a
dATP, dCTP, dGTP, dTTP mix (120mMeach), 3ml (0.75mM)
magnesium chloride (MgCl2) 10ml Buffer IV, 5ml DMSO, 1ml
each of 3¢and 5¢primer sequence, 49.9ml water and 1mCi a-32P-
dCTP. The amplification of the N-rasfragment was performed
using the forward primer 5¢-GCC TGG TTA CTG TGT CCT GT-3
and the reverse primer 5¢-GCC AGC CAC ATC TAC AGT AC-3¢.
PCR was carried out using a Perkin-Elmer 480 thermal cycler, an
initial 2 min denaturation step at 94°C was followed by 25 cycles
of 94°C, 55°C and 72°C for 1min each, with a final incubation of
4min at 72°C at the end of the cycling. These conditions were
chosen to ensure that the PCR reaction was still in the exponential
phase when the reaction was stopped.
Aliquots of 40ml of reaction mixture were precipitated with
1ml ice-cold 5% w/v trichloroacetic acid-20mMtetrasodium
pyrophosphate (TCA). The precipitate was captured on Whatman
GF/C filters with unincorporated a-32-P-dCTP washed through with
10ml of the TCA solution followed by 10ml of absolute ethanol.
The filters were placed in scintillation fluid and the PCR product
quantified by measuring counts per minute (cpm). DNA content
was measured using the Burton assay and cpm mg–1 DNA calcu-
lated with these results used to calculate the lesion index for each
sample.
The lesion index was calculated using the formula-ln Ad/A
where A represents cpm from control sample and Ad represents
cpm from treated samples. Controls containing 25% and 50% of
the control sample were included to ensure that the PCR was quan-
titative.
Microscopy
Attached (control) cells harvested by incubation with trypsin and
detached cells generated from the CH1, CH1cisR and SKOV-3
cell lines following exposure to 7.6mM28mMand 81mMJM216
(2 ´IC50) respectively, were collected, centrifuged and suspended
in 1mg ml–1 propidium iodide. Morphology was examined by
fluorescent microscopy after a 10 min incubation at room
temperature.
Field inversion gel electrophoresis
Attached and detached cells were collected as above.
Approximately 5 ´105 cells were incubated for 1h at 37°C in
100ml lysis buffer (200mMTris, 100mMEDTA, 2% SDS)
containing 1mg ml–1 proteinase K and RNAase (heat-inactivated)
final concentration. Aliquots of cell lysate were added directly to
the gel (1% agarose in TAE buffer), and the wells sealed with 1%
low melting-point agarose. Field inversion gel electrophoresis
(FIGE) was performed with 1 ´TAE (40mMTris, 20mMsodium
acetate, 1mMEDTA) using a Bio Rad FIGE Mapper. Horizontal
gels were run for 20h with a forward voltage of
10V cm–1 and reverse of 7V cm–1 with linear ramping T1 = 1s to
T2 = 12s. The temperature of buffer was controlled to 14°C using
a Bio-Rad 1000 ‘mini chiller’. Sigma Pulse Marker 1 fragments of
0.1–200kb in size were run with the samples.
Cell cycle analysis
This was carried out as outlined in Ormerod et al (1996). Briefly,
cells were collected by centrifugation and suspended in 200ml ice-
cold PBS and fixed by the addition of 1.8ml ice-cold 70% ethanol,
for at least 30min on ice. Fixed cells were centrifuged and the
pellets suspended in 800ml PBS, 100ml (1mg ml–1) RNAase and
100ml of PI (200mg ml–1) and incubated at 37°C for at least
30min, then overnight at 4°C. Flow cytometry was carried out on
a Coulter Elite equipped with a Spectra-physics argon-ion laser
with an output of 200mW at 488nm. Typically data from 2 ´104
cells were analysed with forward and orthogonally scattered light
and red fluorescence (peak and integrated area) recorded. DNA
histograms were generated using WinMDI2.6 Windows Multiple
document Interface Flow Cytometry Application (obtained from
the Internet), from which cell cycle data was calculated using soft-
ware employing a Watson algorithm (Ormerod et al, 1987).
Western blot analysis
CH1 and CH1cisR cells were incubated for 2h with 7.6mMand
28mMJM216 respectively and harvested as above (see measure-
ment of Pt bound to DNA) at 5, 16 and 24h following removal of
drug. Drug additions were staggered so as to facilitate simulta-
neous collection of all time points. Following two washes in
ice-cold PBS the resultant cell pellets from control and treated
samples were resuspended in 300ml of lysis buffer (150mMNaCl,
50mMTris–HCl) to which was added 500ml of 20mMphenyl-
methylsulphonyl fluoride (PMSF), 100ml sodium orthovanadate
(10mMstock), 100ml NP40, 100ml 20% SDS, 2ml aprotinin
(10mg ml–1 stock) and 2ml leupeptin (10mg ml–1 stock) and incu-
bated on ice for 1h. Lysis was aided by pipetting using a Gilson
P200 pipette. The lysed samples were centrifuged at 12000rpm at
4°C for 15min and the supernatant collected for analysis. Protein
content was determined using the Pierce BCA protein detection
kit. Samples were diluted with water to ensure that identical
concentrations of protein were loaded onto the gel and then diluted
1/2 with Laemmli buffer and incubated at 95°C for 3min.Gene-specific repair and apoptosis with JM216 1297
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Typically, 50 mg of protein (25-ml sample) and 3 ml of standard
rainbow marker were loaded onto 8–16% Novex precast PAGE
gels and run at 30 mA per gel for 1 h, then transferred to nitro-
cellulose membrane at 300 mA for 2 h. The membranes were
washed twice with PBS containing 0.1% Tween-20 (PBST),
excess liquid was drained off, then the membranes placed in
blocking buffer (154 mM NaCl, 10 mM Tris, 0.5% caesin and
0.02% thimerosal, at pH 7.6) and agitated for 1 h. The membranes
were subsequently washed in PBST for 5 min and probed for the
protein of interest. Following incubation with primary antibody
the membranes were washed 3 3 10 min with PBST and incu-
bated with secondary antibody linked with horseradish peroxidase
for at least 1 h and then detected with ECL reagents by autoradiog-
raphy. The primary antibody used for p53 was the DO-1 mouse
IgG-2a mouse monoclonal detected with anti-mouse IgG linked to
horseradish peroxidase (Amersham).
Statistical analysis
Where appropriate, statistical significance was tested using a two-
tailed Student’s t-test.
RESULTS
Cell growth inhibition by JM216
The concentration of JM216 required to inhibit growth of
CH1cisR cells by 50% (IC50) following a 2 h incubation was
14 mM. Thus the resistance factor (Rf) for the CH1cisR was 3.6.
Platinum accumulation and platinum bound to DNA
with JM216
Following incubation with JM216, intracellular Pt levels were
similar in all three cell lines and increased with increasing levels
of drug (Figure 1A). For example, at 50 mM JM216, intracellular Pt
levels were approximately: CH1 2.73 ± 0.7, CH1cisR 2.39 ± 0.7,
SKOV-3 2.33 ± 0.1 nmol mg–1 protein.
Similarly, there was no cell line-dependent difference in the
levels of Pt bound to DNA (Figure 1B), such that at 50 mM JM216
levels of Pt bound to DNA were approximately: CH1 249 ± 66,
CH1cisR 229 ± 94, SKOV-3 328 ± 192 pmol mg–1 DNA. These
results indicate that per mg, the amount Pt bound to DNA was
roughly 10% that of protein bound Pt. Furthermore, by calculating
the expected levels of Pt at equitoxic levels of drug, it could be
demonstrated that the resistant cell lines possessed higher intracel-
lular Pt levels and could tolerate higher levels of Pt bound to DNA
(Table 1).
Platinum uptake and Pt/DNA levels were compared in the three
cell lines following 50 mM cisplatin and JM216 (Table 2).
Intracellular Pt levels were on average 1.8-fold higher with
JM216. However, levels of Pt bound to DNA were similar for both
drugs.
Gene-specific repair of Pt/DNA lesions using QPCR
Initially, the levels of Pt/DNA lesions in the N-ras gene were
measured in CH1, CH1cisR and SKOV-3 cells immediately
following a 5 h incubation with 25 mM cisplatin and then at 24 h
following the removal of drug, using the technique described by
Grimaldi et al (1994) and Koberle et al (1996).
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Figure 1 Pt accumulation (A) and Pt bound to DNA (B) the CH1 (n),
CH1cisR (s) and SKOV-3 (•) following a 2 h incubation with a range of
JM216 concentrations (10–100 mM). Error bars = s.d. where n = at least 3
Table 1 Expected intracellular and Pt bound to DNA levels at IC50
concentrations of JM216 calculated from data generated for Figure 1 A and B
Cell line nmoles Pt mg–1 protein pmoles Pt mg–1 DNA
at IC50 at IC50
CH1 0.16 19.7
CH1cisR 0.71 85.7
SKOV-3 1.77 234.6
Table 2 Comparison of intracellular Pt levels following 2 h incubation with
50 mM JM216 and cisplatin. Error bars = s.d. where n = 3; n = 2 for cisplatin
Pt mg–1 protein
Cell line nmoles Pt mg–1 protein pmoles Pt mg–1 DNA
JM216 Cisplatin JM216 Cisplatin
CH1 2.7 ± 0.7 1.3 249 ± 66 226 ± 6
CH1cisR 2.3 ± 0.7 1.5 229 ± 94 174 ± 44
SKOV-3 2.3 ± 0.1 1.4 328 ± 192 197 ± 651298 CF O’Neill et al
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The mean levels of Pt/DNA adducts in the N-ras gene were
similar in the two resistant cell lines but approximately 50% lower
in the CH1-sensitive cell line, though the difference was not quite
statistically significant (Figure 2). However, by 24 h following
removal of drug, both the resistant cell lines exhibited significantly
reduced levels of lesions (P < 0.05) in this gene compared with the
CH1 cell line. In contrast, the number of lesions increased with
time following removal of cisplatin in the CH1 cell line.
Subsequent experiments were carried out with 2 ´ IC50 of
JM216, which for each cell line equated to 7.6 mM, 28 mM and
81 mM in the CH1, CH1cisR and SKOV-3 respectively. All the cell
lines displayed an ability to repair the lesions induced by JM216
(Figure 3A). Interestingly, while both the CH1cisR and SKOV-3
cell lines contained comparable levels of lesions at 5 h, these
levels were approximately 60% lower than in the sensitive CH1
cell line (P < 0.05 vs the SKOV-3). By 24 h, the CH1, CH1cisR
and SKOV-3 had removed 32%, 72% and 67% respectively, of the
initial lesions formed, but the difference between sensitive and
resistant cell lines was not quite significant. Furthermore, in the
CH1-sensitive cell line, there was a difference of almost 4.8-fold
in the lesion index for 7.6 mM JM216 (1.1), compared with 25 mM
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Figure 2 Measurement of induction and repair of lesions induced in the
N-ras gene following a 5 h incubation at 25 mM cisplatin. Error bars = s.d.
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Figure 3 Measurement of induction and repair of lesions induced in the
N-ras gene, (A) following a 5 h incubation at 2 ´ the IC50 concentration of
JM216 (CH1 7.6 mM, CH1cisR 28 mM, SKOV-3 81 mM) for each cell line.
(B) Following a 5 h incubation with 5 mM cisplatin in the CH1.
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cisplatin (0.23). The moderate repair of JM216 induced lesions in
the CH1-sensitive cell line, albeit following a comparatively low
concentration, raised the possibility that minor levels of repair of
cisplatin-induced lesions by this cell line may have been masked
by the 25 mM concentration used. Thus the experiment was
repeated with 5 mM cisplatin which was 2 ´ IC50 for the CH1
(Figure 3B). Initial levels of lesions were low, but detectable,
following the 5 h incubation, however, as with the higher concen-
tration of drug, the number of lesions increased over the 24 h
drug-free period.
Cell death induced by JM216
The detachment of cells from the monolayer was measured after a
2 h incubation with 2 ´ and 5 ´ the 2 h IC50 of JM216. The
numbers of attached cells remaining after removal of drug were
calculated as a percentage of the starting cell number, whereas
detached cells were expressed as a percentage of the total number
of cells remaining at each time point (Figure 4A–C) (O’Neill et al,
1996). There was an initial increase in cell number up to 16 h
with 2 ´ IC50 of drug in the three cell lines. Thereafter, cells
detached in a dose- and time-dependent manner with 50%
AB
CD
Figure 5 Fluorescent microscopy showing normal nuclear morphology of CH1 control untreated attached cells (A), and apoptotic nuclei of detached cells from
CH1 (B) 24 h, CH1cisR (C) 24 h and SKOV-3 (D) 48 h, following exposure to 2 ´ the IC50 of JM216
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Figure 6 FIGE of attached and detached cells collected 24 h (CH1 cell
lines) and 48 h (SKOV-3) following a 2 h platinum drug exposure. Lanes 1
and 10 are molecular weight markers; lanes 2 and 6 are attached and
detached CH1 following exposure to 2 ´ IC50 cisplatin. Lanes 3, 4 and 5 are
attached CH1, CH1cisR and SKOV-3 respectively and lanes 7, 8 and 9 their
detached counterparts following exposure to 2 ´ IC50 JM2161300 CF O’Neill et al
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detachment occurring at 48 h for both CH1 cell lines and 72 h for
the SKOV-3 at 2 ´ the IC50.
Morphology
Detached CH1/CH1cisR and SKOV-3 cells were collected 24 h
and 48 h respectively, following incubation with 2 ´ the IC50 of
JM216. These cells exhibited apoptotic morphology with
compacted and fragmented nuclei when compared with attached
control cells where the chromatin was diffuse (Figure 5). Previous
studies have shown that the morphology of attached treated cells is
similar to that of attached control untreated cells (Ormerod et al,
1994a, 1996; O’Neill et al, 1996).
Field inversion gel electrophoresis
FIGE was carried out on samples prepared from cells collected at
24 h (CH1 cell lines) and 48 h (SKOV-3) following a 2 h exposure
to 2 ´ IC50 JM216. Samples collected from CH1 cells 48 h after
incubation with 2 ´ IC50 cisplatin, were run as a positive control
(Figure 6). Discrete DNA fragments of approximately 23–50 kb,
indicative of apoptosis, were detected in the detached cell
population from all three cell lines following JM216 and
following cisplatin in the CH1. This was absent from the attached
cells. However, there was evidence of fragmentation in the
attached cell population of both CH1 cell lines running between
90 and 150 kb, which was absent from the SKOV-3 cell line.
Earlier studies demonstrated that the DNA from attached control
untreated cells does not migrate much beyond the loading point
(Ormerod et al, 1994a, 1996)
Cell cycle analysis
Flow cytometric analysis was carried out from attached cells
collected at various time points after incubation with 2 ´ IC50
JM216 (Figure 7). The main cell cycle effect of JM216 was a slow
down of traverse through S phase, which culminated in a G2 block
occurring from 48 h to 72 h in the CH1 and CH1cisR cell lines
following removal of drug. For example, by 48 h there were
approximately 37.7% and 47% of cells in S phase and G2 phase
respectively in the CH1, compared with 84.8% in S phase and
9.8% in G2 phase for the SKOV-3 (P < 0.05). The S phase effect
in the SKOV-3 still persisted by 72 h with no evidence of a build
up of cells in G2.
P53 induction
The level of p53 was studied in the CH1 and CH1cisR cell lines
before and following a 2 h incubation with 2 ´ the IC50 of JM216
for each cell line. Constitutive levels of p53 were similar in both
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cell lines, but had increased significantly (P < 0.05) in each cell
line by 16 h after removal of drug, with levels beginning to plateau
by 24 h (Figure 8).
DISCUSSION
This study has addressed the cellular pharmacology of JM216 in
one ovarian cell line possessing acquired resistance to cisplatin
(CH1cisR), another cell line possessing intrinsic resistance to
cisplatin (SKOV-3) and a parental-sensitive cell line (CH1).
JM216 exhibited a comparable level of cytotoxicity to that of
cisplatin in the CH1, CH1cisR and SKOV-3 human ovarian cancer
cell lines. For example, in a previous study, the 2 h IC50s for
cisplatin were 2.5 mM, 7.5 mM and 33 mM respectively, for the CH1,
CH1cisR and SKOV-3, the resistant cell lines being three- and
13.5-fold more resistant to cisplatin (O’Neill et al, 1995). Thus
acquired and intrinsic resistance to cisplatin also manifested in
resistance to JM216 in these cell lines.
It has been demonstrated that higher levels of GSH in the
SKOV-3 (Mistry et al, 1991; Kelland et al, 1992b) influence the
biotransformation of JM216 and results in differences in the meta-
bolic profile of this drug in vitro when compared with the more
sensitive CH1 (Raynaud et al, 1996b). Despite these factors, there
was no difference in either uptake or the levels of Pt bound to
DNA between the three cell lines, across a range of JM216
concentrations (10–100 mM). However, when examined in the
context of IC50 concentration, these results indicated that, at
equitoxic concentrations of JM216, intracellular Pt levels were
higher in the CH1cisR and SKOV-3 cell lines, which displayed an
ability to tolerate higher levels of Pt bound to DNA. Interestingly,
when compared at equimolar concentrations, intracellular levels of
Pt for JM216 were marginally higher than for cisplatin in each
of the three cell lines. This may have been due to the greater
lipophilicity of JM216 enhancing its intracellular accumulation.
However, this did not result in higher levels of Pt bound to DNA
for this drug compared with cisplatin.
Gene-specific repair of Pt lesions induced by JM216 in the
N-ras gene occurred in the three cell lines, but to a greater extent
in the CH1cisR and SKOV-3. Initial levels of lesions in the resis-
tant cell lines were approximately twofold less than in the CH1,
and indeed, were similar to the levels remaining in the N-ras gene
of the CH1 24 h after removal of drug. This suggested that the
CH1 was less capable in repairing these lesions than the two
resistant cell lines. A lack of repair capability in the CH1
compared with the CH1cisR and SKOV-3 was demonstrated at a
comparatively higher concentration of 25 mM cisplatin. At this
concentration, only the resistant cell lines demonstrated repair of
lesions in the N-ras gene. Moreover, in the CH1, Pt adduct forma-
tion continued to rise over the 24-h drug-free period. The reason
for this is unclear, previous studies have shown that the formation
of inter-strand cross-links (ISC) increase for up to 5 h following
an initial 2 h incubation with 25 mM cisplatin, which is more
pronounced in the CH1 cell line (O’Neill et al, 1995). It is conceiv-
able that following a 5 h incubation at this concentration of
cisplatin, the formation of these ISC is prolonged or that lesions
are being converted to strand breaks, both of which might hamper
amplification of gene segments by Taq polymerase under these
experimental conditions.
Being mindful of the possibility that low levels of repair in the
CH1 cell line might have been masked by the higher concentra-
tions of cisplatin used, the experiment was repeated at a lower
concentration of 5 mM cisplatin or 2 ´ IC50 in this cell line, which
was roughly equitoxic with 7.6 mM JM216. The CH1 cell line was
still unable to repair the lesions induced by cisplatin at this
concentration and, as with the higher dose, the number of lesions
continued to increase over the 24-h drug-free period. This differ-
ence in the ability to repair the Pt/DNA lesions induced by JM216
in the N-ras gene, but not by cisplatin, may indicate that the type
of lesion formed by JM216 and/or the recognition of these lesions
is different in this cell line. These results are consistent with
studies which have demonstrated that gene-specific repair is an
important mechanism of resistance in cisplatin resistant cell lines
(Zhen et al, 1992; Johnson et al, 1994; Petersen et al, 1996).
JM 216 induced apoptosis in the CH1, CH1cisR and SKOV-3
cell lines at 2 ´ the IC50 concentration of drug for each cell line.
This compliments earlier studies where cisplatin and two novel cis
and trans Pt compounds, JM149 and JM335 were shown to induce
apoptosis in these cell lines (Ormerod et al, 1996; O’Neill et al,
1996). Cells detached in a dose- and time-dependent manner after
removal of drug, with 50% detachment occurring at 48 h for both
CH1 cell lines and 72 h for the SKOV-3, at 2 ´ the IC50. The differ-
ence in the rate of cell death may have been due to the difference
in doubling times for the CH1 pair (17 h) and the SKOV-3 (22 h).
Apoptotic nuclei were detected by fluorescence microscopy
following incubation with PI and the characteristic 23–50 kb DNA
fragment associated with apoptosis was detected by FIGE
(Oberhammer et al, 1993; Ormerod et al, 1994a, 1996; O’Neill
et al, 1996).
Flow cytometric analysis revealed that a slow down in S phase
transit was a prominent cell cycle effect of JM216 in the three cell
lines. This was accompanied by a marked accumulation of cells in
G2 in the CH1 and CH1cisR cell lines by 72 h. However, with the
SKOV-3 cell line, the majority of cells were still in S phase with
no evidence of a build up of cells in G2 at this time point. Similar
cell cycle perturbations were observed with cisplatin in each cell
line (Ormerod et al, 1996) and in the CH1 cell line with JM149
and JM335 (O’Neill et al, 1996), and are consistent with the
observations of other authors (Vaisman et al, 1997; Zaffaroni et al,
1998). Taken together these and other studies indicate that
accumulation of cells in S phase, is a general cell cycle effect of
platinum drugs, which depending on the cell type, is associated
with G2 arrest (Ormerod et al, 1994b, 1996; O’Neill et al, 1996;
Vaisman et al, 1997; Zaffaroni et al, 1998). In the CH1 cell lines,
accumulation of cells in G2 coincided with the point at which
significant apoptosis was occurring. It has been suggested that G2
arrest facilitates repair of DNA damage prior to mitosis and
depending on the success of repair or extent of DNA damage, cells
emerging from G2 either begin to cycle normally or engage
apoptosis (Sorenson and Eastman, 1988; Ormerod et al, 1994b).
Our data suggests that the latter may be occurring in the CH1 cell
lines, despite the repair of Pt lesions induced by JM216.
Recent evidence has shown that the induction of transfected
wild-type p53 at permissive temperatures following irradiation,
produced a G2 block in H1229 NSCLC cells (Winters et al, 1998).
It is possible then, that the generation of a G2 block by JM216 in
the CH1 cell lines could be associated with the induction of p53 by
this drug as both the CH1 and CH1cisR are wild-type for p53 (M
Walton, personal communication; Pestell et al, 1998), levels of
which, increased following exposure to JM216. The work of
Pestell et al, demonstrated that across a panel of human ovarian
carcinoma cell lines, the expression of wild-type p53 corre-
sponded with sensitivity to ionizing radiation and cisplatin. This is1302 CF O’Neill et al
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in agreement with the work of others who have shown that func-
tional status of p53 is thought to be an important determinant of
susceptibility to apoptosis (MclIwrath et al, 1994; Perego et al,
1996). Our data showing the induction of p53 at concentrations
that induced apoptosis, adds further weight to the evidence that
this process may be p53-dependent in the CH1 cell lines.
In conclusion, JM216, in common with other Pt drugs, induced
apoptosis in the CH1, CH1cisR and SKOV-3 cell lines. Apoptosis
was accompanied by a slow down of passage of cells through S
phase in each cell line, and in the CH1 pair by a G2 block.
Increased p53 protein levels were measured at concentrations of
JM216 that induced apoptosis. JM216 exhibited cross-resistance
with cisplatin in the CH1cisR. Intracellular Pt accumulation and
binding to DNA were similar in all three cell lines at equimolar
drug concentrations. However, at equitoxic levels of JM216, both
resistant cell lines exhibited reduced Pt lesion formation in the N-
ras gene and enhanced repair of these lesions compared with the
CH1. Both resistant cell lines, but not the CH1, repaired lesions
induced by cisplatin. Thus resistance to JM216 in these lines may
be mediated through increased tolerance to Pt/DNA adducts,
enhanced gene-specific repair in both resistant cell lines and in
part by the elevated GSH levels in the SKOV-3 cell line. Notably
in a CH1 subline possessing acquired resistance to JM216, as in
CH1cisR, resistance was attributed to increased DNA repair
(Mellish and Kelland, 1994)
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